Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-23T16:22:36.687Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of phosphodiesterase-5 inhibitor on hearing

Published online by Cambridge University Press:  12 January 2009

S Okuyucu ,
O E Guven ,
E Akoglu ,
E Uçar  and
S Dagli
S Okuyucu*
Affiliation:
Department of Otolaryngology, Mustafa Kemal University School of Medicine, Antakya, Hatay, Turkey
O E Guven
Affiliation:
Department of Urology, Mustafa Kemal University School of Medicine, Antakya, Hatay, Turkey
E Akoglu
Affiliation:
Department of Otolaryngology, Mustafa Kemal University School of Medicine, Antakya, Hatay, Turkey
E Uçar
Affiliation:
Department of Internal Medicine, Mustafa Kemal University School of Medicine, Antakya, Hatay, Turkey
S Dagli
Affiliation:
Department of Otolaryngology, Mustafa Kemal University School of Medicine, Antakya, Hatay, Turkey
*
Address for correspondence: Dr Semsettin Okuyucu, Mustafa Kemal Universitesi Tıp Fakultesi, Arastirma Hastanesi, KBB AD, 31100 Antakya, Hatay, Turkey. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Following a report of sudden hearing loss in a patient taking phosphodiesterase type 5 inhibitor, and a Food and Drug Administration announcement concerning this class of drugs, a study was planned to investigate if ototoxicity occurs in patients using phosphodiesterase 5 inhibitor for erectile dysfunction.

Methods:

Eighteen patients with erectile dysfunction who had been using phosphodiesterase 5 inhibitor were included in the study. Audiometric tests were performed on all patients, between the frequencies 250 and 16 000 Hz, before and 1, 5 and 72 hours after drug ingestion.

Results:

Four patients showed a unilateral threshold decrease compatible with ototoxicity criteria; this change was reversible. A statistically significant difference in pre- versus post-drug hearing thresholds was observed in the right ear at 10 000 Hz (p = 0.008). There were no statistically significant hearing threshold differences at any other frequencies (p > 0.05).

Conclusion:

Although temporary ototoxicity was noted in four patients, we could not find any permanent, deleterious effect of phosphodiesterase type 5 inhibitor on hearing thresholds.

Keywords

VardenafilSensorineural DeafnessDrug Toxicity
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 7 , July 2009 , pp. 718 - 722
Copyright
Copyright © JLO (1984) Limited 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Schwarz, ER, Kapur, V, Rodriguez, J, Rastogi, S, Rosanio, S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007;19:139–48CrossRefGoogle ScholarPubMed
2 Padma-Nathan, H. Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness. Int J Impot Res 2006;18:423–31CrossRefGoogle ScholarPubMed
3 Moreira, SG, Brannigan, RE, Spitz, A, Orejuela, FJ, Lipshultz, LI, Kim, ED. Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000;56:474–6CrossRefGoogle ScholarPubMed
4 Morales, A, Gingell, C, Collins, M, Wicker, PA, Osterloh, IH. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69–74CrossRefGoogle ScholarPubMed
5 Polak, K, Wimpissinger, B, Berisha, F, Georgopoulos, M, Schmetterer, L. Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects. Invest Ophthalmol Vis Sci 2003;44:4872–6CrossRefGoogle ScholarPubMed
6 Kiroglu, AF, Bayrakli, H, Yuca, K, Cankaya, H, Kiris, M. Nasal obstruction as a common side-effect of sildenafil citrate. Tohoku J Exp Med 2006;208:251–4CrossRefGoogle ScholarPubMed
7 Trimarchi, M, Salonia, A, Bondi, S, Montorsi, F, Bussi, M. Nasal congestion after visual sexual stimulation with and without sildenafil (Viagra®): a randomized placebo-controlled study. Eur Arch Otorhinolaryngol 2008;265:303–6CrossRefGoogle ScholarPubMed
8 Motamed, M, Sandhu, D, Murty, GE. Sildenafil and nasal obstruction. J Otolaryngol 2003;32:259–61CrossRefGoogle ScholarPubMed
9 Mukherjee, B, Shivakumar, T. A case of sensorineural deafness following ingestion of sildenafil. J Laryngol Otol 2007;121:395–7CrossRefGoogle ScholarPubMed
10 Boucher, R. Phosphodiesterase type 5 inhibitors. FDA Drug Safety Newsletter 2008;1:15–17Google Scholar
11 Fausti, SA, Henry, JA, Schaffer, HI, Olson, DJ, Frey, RH, McDonald, WJ. High frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992;165:1026–32CrossRefGoogle ScholarPubMed
12 American Speech Language Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994;36:11–19Google Scholar
13 Görür, K, Kandemir, O, Unal, M, Ozcan, C. The effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B. Auris Nasus Larynx 2003;30:41–4CrossRefGoogle ScholarPubMed
14 Penido Nde, O, Ramos, HV, Barros, FA, Cruz, OL, Toledo, RN. Clinical, etiological and progression factors of hearing in sudden deafness. Rev Bras Otorrinolaringol (Engl Ed) 2005;71:633–8Google ScholarPubMed
15 Shi, X, Nuttall, AL. The demonstration of nitric oxide in cochlear blood vessels in vivo and in vitro: the role of endothelial nitric oxide in venular permeability. Hear Res 2002;172:73–80CrossRefGoogle ScholarPubMed
16 Hess, A, Labbé, D, Watanabe, K, Bloch, W, Michel, O. Evidence for an Akt-kinase/NO/cGMP pathway in the cochlea of guinea pigs. Eur Arch Otorhinolaryngol 2006;263:75–8CrossRefGoogle ScholarPubMed
17 Shen, J, Harada, N, Nakazawa, H, Yamashita, T. Involvement of the nitric oxide-cyclic GMP pathway and neuronal nitric oxide synthase in ATP-induced Ca2+ signalling in cochlear inner hair cells. Eur J Neurosci 2005;21:2912–22CrossRefGoogle ScholarPubMed
18 Hopkins, DA, Steinbusch, HW, Markerink van Ittersum, M, De Vente, J. Nitric oxide synthase, cGMP, and NO-mediated cGMP production in the olfactory bulb of the rat. J Comp Neurol 1996;375:641–583.0.CO;2-1>CrossRefGoogle ScholarPubMed
19 Cudeiro, J, Rivadulla, C. Sight and insight – on the physiological role of nitric oxide in the visual system. Trends Neurosci 1999;22:109–16CrossRefGoogle ScholarPubMed
20 Gudziol, V, Mück-Weymann, M, Seizinger, O, Rauh, R, Siffert, W, Hummel, T. Sildenafil affects olfactory function. J Urol 2007;177:258–61CrossRefGoogle ScholarPubMed
21 Heinrich, U, Maurer, J, Koesling, D, Mann, W, Forstermann, U. Immuno-electronmicroscopic localization of the alpha(1) and beta(1)-subunits of soluble guanylyl cyclase in the guinea pig organ of Corti. Brain Res 2000;885:6–13CrossRefGoogle Scholar
22 Takumida, M, Anniko, M, Popa, R, Zhang, DM. Localization of soluble guanylate cyclase activity in the guinea pig inner ear. Acta Otolaryngol 2000;120:28–33Google ScholarPubMed
23 Palomar García, V, Abdulghani Martínez, F, Bodet Agustí, E, Andreu Mencía, L, Palomar Asenjo, V. Drug-induced otoxicity: current status. Acta Otolaryngol 2001;121:569–72CrossRefGoogle ScholarPubMed
24 Finegold, H, Mandell, G, Vallejo, M, Ramanathan, S. Does spinal anesthesia cause hearing loss in the obstetric population? Anesth Analg 2002;95:198–203CrossRefGoogle ScholarPubMed
25 Lazo-Saenz, JG, Galvan-Aguilera, AA, Martinez-Ordaz, VA, Velasco-Rodriguez, VM, Nieves-Renteria, A, Rincon-Castaneda, C. Eustachian tube dysfunction in allergic rhinitis. Otolaryngol Head Neck Surg 2005;132:626–9CrossRefGoogle ScholarPubMed
26 Buchman, CA, Doyle, WJ, Swarts, JD, Bluestone, CD. Effects of nasal obstruction on Eustachian tube function and middle ear pressure. Acta Otolaryngol 1999;19:351–5Google Scholar
27 Salvinelli, F, Casale, M, Greco, F, D'Ascanio, L, Petitti, T, Di Peco, V. Nasal surgery and eustachian tube function: effects on middle ear ventilation. Clin Otolaryngol 2005;30:409–13CrossRefGoogle ScholarPubMed